Search Results - "Groen, H.J.M"

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature by van der Wekken, A.J, Saber, A, Hiltermann, T.J.N, Kok, K, van den Berg, A, Groen, H.J.M

“…Abstract Targeted treatment of advanced non-small cell lung cancer patients with afatinib in EGFR mutation or crizotinib in ALK break positive patients results…”
Get full text

The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer by Degens, J.H.R.J., Sanders, K.J.C., de Jong, E.E.C., Groen, H.J.M., Smit, E.F., Aerts, J.G., Schols, A.M.W.J., Dingemans, A.-M.C.

“…•SM, SAT and RA decrease significantly after two lines of chemotherapy.•Low SM index at baseline does not significantly influence OS.•Loss of SM after two…”
Get full text

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC) by Hermans, B.C.M., Derks, J.L., Thunnissen, E., van Suylen, R.J., den Bakker, M.A., Groen, H.J.M., Smit, E.F., Damhuis, R.A., van den Broek, E.C., Stallinga, C.M., Roemen, G.M., Speel, E.J.M., Dingemans, A.-M.C.

“…•PD-L1 ≥ 1% is expressed in 16% of stage IV LCNEC, 5% has expression ≥50%.•PD-L1 staining in LCNEC is comparable to values in SCLC, but lower than in NSCLC.•No…”
Get full text

Structural distress screening and supportive care for patients with lung cancer on systemic therapy: A randomised controlled trial by Geerse, O.P, Hoekstra-Weebers, J.E.H.M, Stokroos, M.H, Burgerhof, J.G.M, Groen, H.J.M, Kerstjens, H.A.M, Hiltermann, T.J.N

“…Abstract Introduction Gaining regular insight into the nature and severity of distress by a psychosocial nurse coupled with referral to psychosocial and/or…”
Get full text

Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic by de Groot, D.J.A, de Vries, E.G.E, Groen, H.J.M, de Jong, S

“…Abstract Most solid tumors express the cyclooxygenase-2 (COX-2) protein, a target of NSAIDs. COX-2 overexpression in tumorsis considered a predictor of more…”
Get full text

Costs of non-small cell lung cancer in the Netherlands by van der Linden, N, Bongers, M.L, Coupé, V.M.H, Smit, E.F, Groen, H.J.M, Welling, A, Schramel, F.M.N.H, Uyl-de Groot, C.A

“…Highlights • Mean hospital costs per NSCLC patient are €33,143 for the entire disease duration. • The estimated €33,143 per patient is similar to other…”
Get full text

Quality of Life Following Stereotactic Ablative Radiation Therapy Versus Surgery for Early-Stage Lung Cancer: Results From the ROSEL Randomized Controlled Trial and a Systematic Review by Louie, A.V, Chen, H, Van Werkhoven, E, Smit, E, Palma, D.A, Paul, M.A, Warner, A, Widder, J, Groen, H.J.M, van Den Borne, B, De Jaeger, K, Rodrigues, G, Slotman, B.J, Senan, S

Get full text

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer by Ciuleanu, T, Tsai, C.-M, Tsao, C.-J, Milanowski, J, Amoroso, D, Heo, D.S, Groen, H.J.M, Szczesna, A, Chung, C.-Y, Chao, T.-Y, Middleton, G, Zeaiter, A, Klingelschmitt, G, Klughammer, B, Thatcher, N

“…Abstract Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can provide similar efficacy to chemotherapy without…”
Get full text

Health Economic Impact of Volume Doubling Time as Biomarker in Lung Cancer Diagnosis by Brinkhof, S, Groen, H.J.M, Siesling, S, IJzerman, M.J

Get full text

PD-0135: Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiatioN by Bollineni, V.R, Koole, M.J.B, Pruim, J, Wiegman, E.M, Groen, H.J.M, Vlasman, R, Halmos, G.B, Langendijk, J.A, Widder, J, Steenbakkers, R.J.H.M

Get full text

'DE NOVO' Quantification of Genotype-Directed Therapy with Afatinib in Metastatic Lung Cancer by Zaim, R, Tran, L, Groen, H.J.M, Uyl-de Groot, C.A

Get full text

OC-0164 METASTASECTOMY NOT BETTER THAN SABR FOR LUNG OLIGOMETASTASES IN A SINGLE INSTITUTION COHORT (N=110) by Widder, J, Klinkenberg, T.J, Ubbels, J.F, Wiegman, E.M, Groen, H.J.M, Langendijk, J.A

Get full text

OC-0326: Coregistration of 18F-FAZA- and 18F-FDG-PET in NSCLC by Bollineni, V.R, Kerner, G.S.M.A, Pruim, J, Steenbakkers, R.J.H.M, Koole, M.J.B, Widder, J, Groen, H.J.M, Langendijk, J.A

Get full text

Blinded and uniform cause of death verification in a lung cancer CT screening trial by Horeweg, N, van Klaveren, R.J, Groen, H.J.M, Lammers, J.-W.J, Weenink, C, Nackaerts, K, Mali, W, Oudkerk, M, de Koning, H.J

“…Abstract Disease-specific mortality is the final outcome of a lung cancer screening trial, therefore cause of death verification is crucial. The use of death…”
Get full text

A Phase II Study of Sorafenlb In Patients with Locally Advanced And/or Metastatic (stage 1MB or IV) Non-small Cell Lung Cancer (NSCLC) with a K-Ras Mutation by Dinqemans, A.M, Mellema, W.W, Groen, H.J.M, van Wijk, A, Burgers, S, Kunst, P.W.A, Thunnissen, F.B, Heideman, D.A.M, Smit, E.F

Get full text

9028 POSTER Gemcitabine and Cisplatin Followed by Concurrent Gemcitabine and Radiotherapy or Sequential Radiotherapy Alone in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) by Kerner, G.S.M.A, van Dullemen, L.F.A, Wiegman, E.M, van der Leest, A.H.D, Widder, J, Ubbels, J.F, Hiltermann, T.J.N, Groen, H.J.M

Get full text

Non-small cell lung carcinoma of the superior sulcus: Favourable outcomes of combined modality treatment in carefully selected patients by Kappers, I, Belderbos, J.S.A, Burgers, J.A, van Zandwijk, N, Groen, H.J.M, Klomp, H.M

“…Summary The combination of radiotherapy and concurrent chemotherapy followed by surgery (trimodality treatment) is currently regarded as optimal treatment for…”
Get full text

Inaccurate clinical nodal staging of non-small cell lung cancer: Evidence from the MRC LU22 multi-centre randomised trial by Navani, N, Nankivell, M, Stephens, R.J, Parmar, M.K.B, Gilligan, D, Nicolson, M, Groen, H.J.M, van Meerbeeck, J.P

Get full text

Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension by Steenhuis, LH, Groen, HJ, Koeter, GH, van der Mark, TW

“…The transfer factor of the lung for carbon monoxide (TL,CO) is decreased in patients with pulmonary hypertension. The pulmonary membrane diffusion capacity…”
Get full text

Short Induction Chemotherapy Followed by Immediate Concurrent Radiotherapy and Gemcitabine in the Treatment of Non-Small Cell Lung Cancer (NSCLC) by Ubbels, J.F, Bijl, H.P, Wester, G, Van Gameren, M.M, Van der Leest, A.H.D, Widder, J, Groen, H.J.M, Langendijk, J.A

Get full text